secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0000950170-21-005305
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus closes Gilead amendment; receives $725M option fees for 3 programs
------------------------------------------------------------------------

- Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.
- Gilead acquires rights to anti-TIGIT (domvanalimab/AB308), adenosine antagonist (etrumadenant), CD73 (quemliclustat).
- Gilead to pay $725 million in option fees, expected early Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/0000950170-21-005305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017021005305/rcus-20211221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer